JACC. Case reports · 2026
Co-Administration of Mavacamten and Tacrolimus in a Renal Transplant Recipient With Obstructive Hypertrophic Cardiomyopathy.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Willeford Andrew, Faravardeh Arman, Silva Enciso Jorge, Bui Quan M
Аннотация
BACKGROUND: Mavacamten is a cytochrome P450 (CYP)3A4 inducer with a product label recommending careful monitoring alongside CYP3A4 substrates. Data characterizing its interaction with tacrolimus, a narrow-therapeutic-index immunosuppressant and CYP3A4 substrate, are lacking.
CASE SUMMARY: A 62-year-old woman kidney transplant recipient with symptomatic obstructive hypertrophic cardiomyopathy was started on mavacamten 5 mg daily. Over 5 months, serial monitoring showed stable, therapeutic tacrolimus troughs (5.9-7.8 ng/mL) without dosage adjustments, alongside significant clinical improvement in obstructive symptoms.
DISCUSSION: This case uniquely details the longitudinal pharmacokinetic interaction between mavacamten and tacrolimus. This is highly relevant because pharmacokinetic models suggest CYP3A4 induction is dose-dependent; thus, safety demonstrated at 5 mg may not apply to higher regimens like 15 mg.
TAKE-HOME MESSAGES: Low-dose mavacamten and tacrolimus coadministration is feasible. However, rigorous tacrolimus therapeutic drug monitoring remains essential, especially during mavacamten dose escalation.
CASE SUMMARY: A 62-year-old woman kidney transplant recipient with symptomatic obstructive hypertrophic cardiomyopathy was started on mavacamten 5 mg daily. Over 5 months, serial monitoring showed stable, therapeutic tacrolimus troughs (5.9-7.8 ng/mL) without dosage adjustments, alongside significant clinical improvement in obstructive symptoms.
DISCUSSION: This case uniquely details the longitudinal pharmacokinetic interaction between mavacamten and tacrolimus. This is highly relevant because pharmacokinetic models suggest CYP3A4 induction is dose-dependent; thus, safety demonstrated at 5 mg may not apply to higher regimens like 15 mg.
TAKE-HOME MESSAGES: Low-dose mavacamten and tacrolimus coadministration is feasible. However, rigorous tacrolimus therapeutic drug monitoring remains essential, especially during mavacamten dose escalation.